Molecular Residual Disease

Circulating tumor DNA-based detection of molecular residual disease appeared to be highly prognostic of patient outcomes, according to data presented at ASCO Gastrointestinal Cancers Symposium.

Healio spoke with Ash A. Alizadeh, MD, PhD, associate professor, divisions of oncology & hematology, Stanford Cancer Institute, about the potential of liquid biopsy in lymphoma.